drugset / Trial / NCT01693393

Low Dose Cyclosporin A in Primary Sjögren Syndrome

NCT01693393

Phase 2 Completed 30 enrolled Charite University, Berlin, Germany
NaSingle-groupOpen-labelTreatment

Summary

Sandimmun optoral (Cyclosporin A) is used for the musculoskeletal manifestations of Primary Sjögren Syndrome

Timeline

Start
2010-03
Primary completion
2014-10
Completion
2014-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclosporine Peptide 2 mg/kg

Indications